Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Jabłkowski

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Scientific Reports|March 18, 2022
Digit ratios and their asymmetries as risk factors of developmental instability and hospitalization for COVID-19A Kasielska-Trojan, J T Manning, M Jabłkowski, et al.
Scientific Reports|May 23, 2022
Author Correction: Digit ratios and their asymmetries as risk factors of developmental instability and hospitalization for COVID-19A Kasielska-Trojan, J T Manning, M Jabłkowski, et al.
Alimentary Pharmacology & Therapeutics|September 10, 2016
Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER studyR Flisiak, E Janczewska, M Wawrzynowicz-Syczewska, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Scientific Reports|March 18, 2022
Digit ratios and their asymmetries as risk factors of developmental instability and hospitalization for COVID-19A Kasielska-Trojan, J T Manning, M Jabłkowski, et al.
Scientific Reports|May 23, 2022
Author Correction: Digit ratios and their asymmetries as risk factors of developmental instability and hospitalization for COVID-19A Kasielska-Trojan, J T Manning, M Jabłkowski, et al.
Alimentary Pharmacology & Therapeutics|September 10, 2016
Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER studyR Flisiak, E Janczewska, M Wawrzynowicz-Syczewska, et al.
Pageof 2